Gelteq Secures Up To $3.5M Convertible Debt, Initial $1M Funded
GELS is trading near its 52-week low of $0.387 (9.0% above the low) on light trading volume (0.1× avg).
Summary
Gelteq Ltd secured up to $3.5 million in convertible debt financing, with an initial $1.0 million funded immediately, providing critical capital for the micro-cap company amidst Nasdaq non-compliance. The financing terms are dilutive but include a conversion floor price above the current stock price, indicating investor confidence.
Key Events · Financing and Capital Events · GELS
-
Secured $3.5 Million Convertible Debt
Gelteq Ltd entered an agreement for up to $3.5 million in convertible debt financing, following a news announcement on May 12, 2026.
-
Initial $1.0 Million Funded Immediately
An initial tranche of $1.0 million (net of $150,000 original issue discount) was funded immediately via a convertible promissory note.
-
Contingent Second Tranche of $2.5 Million
An additional $2.5 million (net of $375,000 original issue discount) is contingent on shareholder approval and the absence of Trigger Events.
-
Conversion Terms Above Current Market Price
The notes are convertible at 93% of the lowest 5-day volume weighted average price, with a floor price of $0.50 per share, which is a premium to the current stock price of $0.422.
Analysis · GELS · Life Sciences
This financing is critical for Gelteq, a micro-cap company with a market cap of $4.52 million, especially given its recent Nasdaq non-compliance notice. The $3.5 million in potential funding represents a substantial capital injection, providing a lifeline for operations and potentially addressing listing requirements. While the terms are highly dilutive if fully converted and include significant original issue discounts and investor-protective covenants, the conversion floor price of $0.50 per share (above the current stock price of $0.422) suggests the institutional investor sees future value in the company. The immediate funding of $1.0 million provides near-term liquidity, with the remaining $2.5 million contingent on shareholder approval.
At the time of this filing, GELS was trading at $0.42 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.5M. The 52-week trading range was $0.39 to $3.51. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.